Kenvue Inc. Faces Challenges in Q2 Sales
Kenvue Inc. (KVUE) has reported disappointing sales figures for the second quarter, particularly from its well-known consumer products like Band-Aid, Listerine, and Neutrogena. Alongside this, the CEO announced their departure from the company. This news has sparked a significant increase in put options trading today.
As of now, KVUE is priced at $21.59, a far cry from what investors might have hoped for following the lackluster first-quarter results announced on May 8. Still, some might see this as a potential buying opportunity.
Yesterday, Kenvue’s preliminary sales indicated a 4% drop, with “organic” sales at a negative 4.2%. The company plans to update its 2025 outlook on August 7, following the previous disappointing quarter.
In the first quarter, Kenvue reported a year-over-year sales decline of 3.9%. Interestingly, while total margins climbed from 57.6% to 58%, the operating profit margin also saw a slight increase from 14.1% to 14.9%. However, they hinted at a low operating profit forecast for the full year in 2025, though specifics were not provided. They aim to “mitigate” the effects of tariffs on their performance moving forward.
The announcement of the CEO’s exit—just months after the CFO was released—indicates a broader shake-up within the company’s senior management.
Kenvue is looking to enhance shareholder value, but the details about how they plan to do this remain vague. Perhaps this is why there’s been a surge in activity surrounding put options concerning KVUE stock.
A report from Barchart reveals that more than 5,000 put options have traded for an expiration on July 25 at a $21.00 strike price, a significant uptick compared to previous contracts at that level. This price is somewhat lower than today’s, indicating it’s out of the money. Buyers of these puts expect KVUE to dip below $20.76.
Conversely, sellers who may have received a bid of only 18 cents see an immediate yield of 0.86%. Meanwhile, those opting for midpoint premiums can anticipate around 1.14%. On average, put sellers are looking at yields close to 1.0% as they wait for the expiration in nine days.
If KVUE shares do fall to that $21.00 mark before July 25, it might present a valuable buying chance based on the stock’s projected outlook.
There’s growing concern that tariffs could adversely affect Kenvue’s operating and net profits. The question is, has this concern already been accounted for in the stock price?
Analysts anticipate earnings per share of $1.13 this year, with a slight increase to $1.21 next year. This leads to KVUE stocks being valued at about 18.5 times their earnings (P/E ratio).
This 18.45x metric is a slight uptick from what we’ve observed over the last couple of years; Morningstar notes a forward P/E multiple of approximately 16.4 for 2023 and 2024. Based on this, the inventory could be valued at around $19.19, indicating an 11% potential decline per share. With 2026 EPS, the stock might hold a value of $19.84, suggesting an 8% downside from current levels.
However, the company claims it intends to implement measures to enhance shareholder value. Let’s hope these efforts positively influence stock valuations.
Interestingly, those purchasing puts could potentially reap greater rewards than those selling them.
Ultimately, KVUE’s shares seem to be in a transitional phase until there’s further clarity from the company regarding its 2025 outlook and the impact of tariffs.
Investors might want to consider their strategies carefully, especially with the unusual options activities occurring, until things are more transparent.
